Tag: ACC.25
ACC.25: Semaglutide improves walk distance for PAD patients with diabetes
Semaglutide significantly improved maximal walking distance in people with symptomatic peripheral arterial disease (PAD) and type 2 diabetes in a trial designed to evaluate...